This session aims to illuminate the cutting-edge technical approaches of AI-driven biologics drug discovery companies. Speakers will explore the ongoing R&D efforts in developing platforms and pipelines, delineate their roles within the life sciences industry, and provide insights into the current competitive landscape. Additionally, speakers will facilitate a robust discussion to critically examine the challenges and limitations of various AI approaches in the current biologics drug discovery landscape, encouraging a deeper comprehension and engagement from all attendees. The session will also offer industry experts early insights into advanced developments, fostering opportunities for involvement and collaboration.